Comparative outcomes in different aortic valve stenosis surgeries and implications of TAVR surgery for cirrhotic patients: A retrospective cohort study

Maria Winte a, Krysta Contino b, Aditi Trivedi a, Nikhita Dharbhamulla b, John Gaughan a, Christopher Deitch b, Sangita Phadtare a, *

a Cooper Medical School of Rowan University, USA
b Cooper University Health Care, USA

ARTICLE INFO

Keywords:
SAVR
Mini-SVR
TAVR
Cirrhosis

ABSTRACT

Background: Our hospital system is committed to service to medically underserved, low-income, and minority populations. It is located in a city wherein 37% of people live in poverty. Overall cost effectiveness is part of our patient care quality improvement. Cirrhotic patients are at higher risk for cardiac surgery as cardiopulmonary bypass triggers the release of substances that mimic the physiologic changes seen in cirrhosis. We compared outcomes of surgeries performed for the treatment of aortic valve stenosis, surgical aortic valve replacement (SAVR), mini-surgical valve replacement (mini-SVR), and transcatheter aortic valve replacement (TAVR) with attention to cirrhotic patients.

Methods: This retrospective cohort study looked at the medical records of 457 patients. Demographic data, substance abuse, pre-existing diagnoses, length of stay, outcomes, and lab values were collected for each patient pre- and post-surgery. Fisher’s exact test or chi square was used to compare categorical characteristics and outcomes among groups. ANOVA for repeated measures was utilized to compare group differences of continuous measurements over time.

Results: Despite having the highest average age of patients and higher incidence of pre-existing comorbidities, post-operative complications such as arrhythmia, hyponatremia, and coagulopathy developed to a lesser extent in TAVR patients. The length of post-surgery hospital stay was also the least in TAVR patients. TAVR offered better post-operative outcomes in cirrhotic patients as well.

Conclusions: TAVR showed better post-surgical outcomes and provide an option for cardiac surgery for cirrhotic patients. This data will be useful for enabling a patient-centered decision-making process in our population.

1. Introduction

Our hospital system is committed to service to medically underserved, low-income, and minority populations. Our hospital is located in a city wherein 37% of people live in poverty. The most common ethnic group living below the poverty line in our city is Hispanic while that in the entire county is Caucasian. Consideration of cost effectiveness especially with respect to post-surgery outcomes is one of the aspects of our continuous patient care quality improvement. Aortic stenosis is the most common native valve disease, affecting up to 5% of the elderly population. Surgical aortic valve replacement (SAVR) has been the common surgery used to treat these patients. While SAVR reduces symptoms and improves survival, the surgical risk is significantly increased in patients with co-morbidities and also in elderly patients. Different groups have evaluated the outcomes of transcatheter aortic valve replacement (TAVR) as compared to SAVR in specific populations with somewhat mixed results [1–7].

In this study, we compared outcomes of three types of surgeries performed for treatment of aortic valve stenosis, SAVR, mini-surgical valve replacement (mini-SVR) and TAVR for our patient population. We hypothesized that TAVR patients have decreased intra-operative complications, length of hospital stay, and develop fewer post-operative complications compared to patients who undergo SAVR and mini-SVR, as TAVR is less invasive and can obviate the need for...
cardiopulmonary bypass. Recently, it has been suggested that in patients who are at increased surgical risk, the decision between SAVR and TAVR should be made by the cardiology team according to individual patient characteristics [8]. We thus evaluated our patient population who had undergone one of these three surgeries with respect to their characteristics and surgical outcomes.

Patients with liver cirrhosis are deemed a high risk population for cardiac surgery and have been noted to have high morbidity and mortality [9]. It has been previously suggested that cardiopulmonary bypass triggers the release of various substances that mimic the physiologic changes seen in cirrhosis such as coagulopathy and other end organ dysfunction. As such, some have hypothesized that avoiding extracorporeal circulation may lead to improved outcomes [10]. Other studies have found lower post-procedural complications and mortality when comparing TAVR to SAVR [11]. It has also been found that the 30 day mortality rate in patients with cirrhosis undergoing TAVR was not higher than those without cirrhosis [12]. Our goal in this study was thus also to evaluate surgical outcomes in cirrhotic versus non-cirrhotic patients.

2. Methods

The study was approved by the University Health Care Institutional Review Board. A retrospective chart review study was carried out for patients who had undergone SAVR, mini-SVR or TAVR between July 1st, 2012 and June 30th, 2017 (researchregistry5766). Patients under the age of 18 years were excluded from the chart review. International Classification of Diseases, Ninth Revision code (ICD-9) was utilized to identify patients who underwent surgical aortic valve replacement or mini-aortic valve replacement and a departmental database was utilized for identification of patients who had undergone TAVR. In total, we reviewed charts of 457 patients: 117 SAVR patients, 124 mini-SVR patients, and 216 TAVR patients. Demographic data (age, sex, height, weight BMI, ethnic group), substance abuse history, pre-existing medical conditions and surgical outcomes were collected for each patient. All complications described in Table 3 except death were considered an outcome if it occurred within 30 days of surgery. Death was considered an outcome if it occurred within 1 year of the procedure. Three post-surgical complications were observed to be significantly lower in the TAVR patients namely, arrhythmia (atrial fibrillation) (p < 0.0001), hypotension (p = 0.0011), and coagulopathy (p < 0.0001). We found no difference in ongoing myocardial ischemia (OMI) following TAVR, SAVR, or mini-SVR (p = 0.1665). Valve failure was observed more frequently in TAVR patients than SAVR and mini-SVR patients (p = 0.0083); 4% of TAVR patients showed valve failure. Seventeen percent of TAVR patients as compared to the 5–6% SAVR and mini-SVR patients showed hypoalbuminemia. One study reported major late bleeding complications much higher than those who underwent SAVR (65.9 ± 11.9) or mini-SVR (69.5 ± 11.8) procedures. Percentage of females who underwent TAVR was higher (55%) as compared to those who underwent SAVR (44%) mini-SVR (40%). The ethnic breakdown of our patient population revealed that majority were Caucasians (75%, 83% and 89% for SAVR, mini-SVR and TAVR procedures, respectively).

BMI of the TAVR patients was lower on average (27.8) compared to that of SAVR (30) or mini-SVR (30.5) patients. However, considering the average higher age of the TAVR patients, lower BMI values may not necessarily be indicative of lower obesity in this group. Approximately half of the SAVR and mini-SVR patients reported past and current alcohol use, with the percentage being remarkably lower (23%) in the TAVR patients. The data reported on the alcohol use was not quantitative and thus could not allow for conclusions to be drawn regarding alcohol abuse. Patients (53–68%) belonging to all three categories had past smoking history, but that percentage was significantly reduced across the board for current use. The majority of patients denied illicit drug use. Table 2 shows pre-existing medical conditions of the patients undergoing each type of surgery. Hypertension, hyperlipidemia, coronary artery disease, concomitant cardiac disease and atrial fibrillation were observed as pre-existing conditions more significantly in the patients who underwent TAVR surgery. Psychiatric conditions were more common in SAVR and mini-SVR patients. Overall, the TAVR group had significantly higher age as well as pre-existing comorbidities.

Next we compared the post-surgical outcomes in all three groups of patients. The length of the post-surgical hospital stay was 9.06 (±5.02), 7.08 (±3.65) and 6.12 (±5.59) days in SAVR, mini-SVR and TAVR, respectively. Table 3 shows post-surgery complications observed in each group of the patients. We collected 30 day and 90 day post-operative data for each patient. All complications described in Table 3 except death developed within 1–4 days post-surgery, and prior to discharge from the hospital. Death was considered an outcome if it occurred within 1 year of the procedure. Three post-surgical complications were observed to be significantly lower in the TAVR patients namely, arrhythmia (atrial fibrillation) (p < 0.0001), hypotension (p = 0.0011), and coagulopathy (p < 0.0001). We found no difference in ongoing myocardial ischemia (OMI) following TAVR, SAVR, or mini-SVR (p = 0.1665). Valve failure was observed more frequently in TAVR patients than SAVR and mini-SVR patients (p = 0.0083); 4% of TAVR patients showed valve failure. Seventeen percent of TAVR patients as compared to the 5–6% SAVR and mini-SVR patients showed hypoalbuminemia. One study reported major late bleeding complications

| Characteristic | SAVR(n = 117) | Mini-SVR(n = 124) | TAVR(n = 216) | P-value |
|---------------|--------------|------------------|--------------|--------|
| Age (years)   | 65.9 ± 11.9  | 69.5 ± 11.8      | 82.7 ± 7.2   | <0.001 |
| BMI           | 30.0 ± 7.2   | 30.5 ± 6.3       | 27.8 ± 6.2   | 0.003  |
| Male          | 65 (56%)     | 75(60%)          | 99(46%)      | 0.0220 |
| Female        | 52(44%)      | 49(40%)          | 119(50%)     |        |
| Race/ethnicity|              |                  |              | <0.0001|
| White         | 88(75%)      | 103(83%)         | 192(89%)     |        |
| African American| 20(17%)  | 6(5%)            | 6(3%)        |        |
| Hispanic      | 6(5%)        | 13(10%)          | 8(4%)        |        |
| Other         | 3(3%)        | 2(2%)            | 11(5%)       |        |
| Alcohol       |              |                  |              |        |
| History of alcohol use | 55(47%) | 70(56%) | 50(23%) | <0.0001 |
| Current alcohol use | 51(44%) | 65(52%) | 44(20%) | <0.0001 |
| Smoking       |              |                  |              |        |
| History of smoking | 79(68%) | 66(53%) | 123(57%) | 0.0542 |
| Currently smokes | 21(18%) | 11(9%) | 7(3%) | <0.0001 |
| Drug Use      |              |                  |              |        |
| History of illicit drug use | 7(6%) | 6(5%) | 2(1%) | 0.0132 |
| Current illicit drug use | 5(4%) | 6(5%) | 21(1%) | 0.0436 |
comparison between TAVR non-cirrhotic and TAVR cirrhotic patients. As seen from Table 4, the pre-existing medical conditions were comparable between these two groups of patients, except for hyperlipidemia, which was higher in TAVR non-cirrhotic patients ($p = 0.02$). The post-surgical length of stay at the hospital was same in both groups of TAVR patients ($6.12 \pm 5.59$ days). As seen from Table 5, post-surgical outcomes were comparable between the non-cirrhotic and cirrhotic TAVR patients, suggesting that patients with cirrhosis were able to tolerate TAVR surgery well. The only worse post-surgical outcome observed in TAVR cirrhotic patients was congestive heart failure (Table 5).

4. Discussion

Our data showed that TAVR patients had better post-surgical outcomes compared to SAVR and mini-SVR. This is especially noteworthy as the TAVR group of patients was significantly older and had higher incidence of pre-existing comorbidities. This is consistent with the report that TAVR may be a better option in elderly patients with comorbidities as it allows implantation of a prosthetic heart valve within the diseased native aortic valve without the need for open heart surgery and cardiopulmonary bypass [14]. As mentioned above, the average age of our patients who underwent the TAVR surgery was much higher than those who underwent SAVR or mini-SVR procedures. Recently, however, there have been concerns about the use of TAVR especially in younger patients, who are otherwise excellent candidates for SAVR due to the unknown long-term outcomes of the TAVR procedure, such as neurological damage. The many under-studied complications and unknown long-term outcomes of the TAVR procedure thus lead to cautionary note for this use of this procedure in low-risk patients [15,16].

It was observed that post-operative complications from cardiac surgery are higher in patients with liver disease increasing their surgical risk such as bleeding complications, post-operative worsening of liver disease and higher incidence of death. Cardiopulmonary bypass is not well tolerated in cirrhotic patients due to possible release of vasoactive substances caused by the bypass [17]. Studies showed that it is possible to achieve lower rates of liver decompensation with TAVR surgery. Arrhythmia, a common and dangerous consequence of cardiac surgery, was decreased with TAVR, making it a superior option for the treatment of aortic valve pathology in cirrhotic patients as well. Cirrhotic and end-stage liver patients are more likely to get general complications and physiological changes in addition to varices, ascites, and portal hypertension. These can make them prone to coagulopathy, infections, and organ dysfunctions [11]. Notably, coagulopathy was a significantly lower post-surgical complication in both of our cirrhotic and non-cirrhotic TAVR patients as compared to SAVR and mini-SVR patients (Tables 3 and 5). Our study had a limitation in that we did not have sufficient number of cirrhotic patients undergoing SAVR and mini-SVR.

### Table 2

| Pre-existing medical condition | SAVR (N = 117) | Mini-SVR (N = 124) | TAVR (N = 216) | $P$ Value |
|-------------------------------|--------------|-------------------|--------------|-----------|
| Hypertension                  | 109 (93%)    | 111 (90%)         | 209 (96%)    | 0.0461    |
| Hyperlipidemia                | 87 (74%)     | 103 (83%)         | 193 (89%)    | 0.0021    |
| Coronary artery disease       | 84 (72%)     | 84 (68%)          | 182 (84%)    | 0.0011    |
| Concomitant cardiac disease   | 55 (47%)     | 31 (25%)          | 146 (67%)    | <0.0001   |
| Atrial fibrillation           | 30 (26%)     | 31 (25%)          | 96 (44%)     | <0.0001   |
| Cancer                        | 22 (19%)     | 31 (25%)          | 65 (30%)     | 0.0797    |
| Chronic kidney disease        | 26 (22%)     | 15 (12%)          | 29 (14%)     | 0.0852    |
| Stroke                        | 11 (9%)      | 15 (12%)          | 39 (18%)     | 0.0772    |
| Peripheral vascular disease   | 18 (15%)     | 18 (15%)          | 43 (20%)     | 0.4082    |
| Rheumatic disease             | 8 (7%)       | 13 (11%)          | 25 (12%)     | 0.3950    |
| Psychiatric conditions        | 29 (25%)     | 35 (28%)          | 28 (13%)     | 0.0009    |

* Two times over baseline values.

### Table 3

| Post-surgery complication | SAVR (n = 124) | Mini-SVR (n = 124) | TAVR (n = 216) | Value |
|---------------------------|---------------|-------------------|---------------|-------|
| Creatinine                | 9 (8%)        | 8 (6%)            | 19 (9%)       | 0.7944 |
| Renal Failure             | 23 (20%)      | 14 (11%)          | 35 (16%)      | 0.075 |
| Bleed                     | 7 (6%)        | 22 (18%)          | 13 (6%)       | 0.0559 |
| Congestive heart failure  | 1 (1%)        | 5 (4%)            | 15 (7%)       | 0.1212 |
| Valve Failure             | 97 (82%)      | 82 (66%)          | 102 (47%)     | <0.0001|
| Ongoing myocardial ischemia| 1 (1%)      | 0 (0%)            | 4 (2%)        | 0.1665 |
| Arrhythmia                | 17 (15%)      | 59 (48%)          | 55 (25%)      | <0.0001|
| Hypertension              | 45 (38%)      | 39 (31%)          | 44 (20%)      | 0.0011 |
| Hypoalbuminemia           | 6 (5%)        | 7 (6%)            | 36 (17%)      | 0.0002 |
| Renal disease             | 0 (0%)        | 14 (12%)          | 14 (6%)       | 0.4082 |
| Death                     | 7 (6%)        | 8 (6%)            | 10 (5%)       | 0.3638  |

(30 days) after TAVR [13]. We did not observe these complications in our TAVR patients.

Our next goal was to compare the three surgical outcomes in cirrhotic versus non-cirrhotic patients, however we had only 5 cirrhotic patients who underwent mini-SVR. It was thus not possible to carry out statistically relevant comparison of outcomes within these two surgery groups with respect to existence of cirrhosis (Tables 4 and 5). Out of the 216 patients who underwent TAVR, 49 had cirrhosis and the remaining 167 were non-cirrhotic. We thus carried out statistical analysis of pre-existing conditions and surgical outcomes of non-cirrhotic and cirrhotic TAVR patients. The $p$ values given in Tables 4 and 5 are only for the comparison between TAVR non-cirrhotic and TAVR cirrhotic patients.

### Table 4

| Pre-existing medical condition | SAVR Non-Cirrhotic (n = 112) | SAVR-Cirrhotic (n = 5) | Mini-SVR Non-Cirrhotic (n = 120) | Mini-SVR-Cirrhotic (n = 4) | TAVR Non-Cirrhotic (n = 167) | TAVR-Cirrhotic (n = 49) | $P$ Value* |
|-------------------------------|-------------------------------|-----------------------|-------------------------------|--------------------------|--------------------------|-----------------------|------------|
| Hypertension                  | 104 (93%)                     | 5 (100%)              | 107 (89%)                     | 4 (100)                  | 159 (95%)                | 49 (100%)             | 0.20       |
| Hyperlipidemia                | 84 (75%)                      | 3 (60%)               | 100 (83%)                     | 3 (75)                   | 153 (92%)                | 39 (80%)              | 0.02       |
| Coronary artery disease       | 79 (71%)                      | 5 (100%)              | 82 (68%)                      | 2 (50)                   | 137 (82%)                | 44 (90%)              | 0.27       |
| Concomitant cardiac disease   | 52 (46%)                      | 3 (60%)               | 30 (25%)                      | 1 (25)                   | 111 (66%)                | 34 (69%)              | 0.73       |
| Atrial fibrillation           | 28 (25%)                      | 2 (40%)               | 29 (24%)                      | 2 (50)                   | 73 (44%)                 | 23 (47%)              | 0.62       |
| Cancer                        | 22 (20%)                      | 0 (0%)                | 29 (24%)                      | 2 (50)                   | 47 (28%)                 | 18 (37%)              | 0.29       |
| Chronic kidney disease        | 24 (21%)                      | 2 (40%)               | 15 (13%)                      | 0 (0)                    | 19 (11%)                 | 10 (20%)              | 0.10       |
| Stroke                        | 11 (10%)                      | 0 (0%)                | 14 (12%)                      | 0 (0)                    | 33 (20%)                 | 6 (12%)               | 0.29       |
| Peripheral vascular disease   | 17 (15%)                      | 1 (20%)               | 18 (15%)                      | 0 (0)                    | 34 (20%)                 | 9 (18%)               | 0.84       |
| Rheumatic disease             | 8 (7%)                        | 0 (0%)                | 13 (11%)                      | 0 (0)                    | 21 (13%)                 | 4 (8%)                | 0.61       |
| Psychiatric disease           | 29 (26%)                      | 0 (0%)                | 35 (29%)                      | 0 (0)                    | 22 (13%)                 | 6 (12%)               | 1.00       |

* $P$ values are given only for the comparison between TAVR non-cirrhotic and TAVR cirrhotic patients.
Table 5
Comparison of post-surgical outcomes between non-cirrhotic and cirrhotic surgery patients.

| Post-surgery complication | SAVR Non-Cirrhotic (N = 112) | SAVR-Cirrhotic (N = 5) | Mini-SVR Non-Cirrhotic (n = 120) | Mini-SVR-Cirrhotic (n = 4) | TAVR Non-Cirrhotic (N = 167) | TAVR-Cirrhotic (n = 49) | P Value* (TAVR patients) |
|---------------------------|-------------------------------|------------------------|----------------------------------|---------------------------|-----------------------------|--------------------------|--------------------------|
| Creatinine                | 9(8%)                         | 0(0%)                  | 8(7%)                            | 0(0%)                     | 13(8%)                      | 6(12%)                   | 0.2683                   |
| Renal Failure             | 21(19%)                       | 2(40%)                 | 14(12%)                          | 0(0%)                     | 23(14%)                     | 12(24%)                  | 0.0912                   |
| Bleed                     | 7(6%)                         | 0(0%)                  | 2(2%)                            | 0(0%)                     | 8(5%)                       | 5(10%)                   | 0.0974                   |
| Congestive heart failure  | 6(5%)                         | 0(0%)                  | 5(4%)                            | 0(0%)                     | 9(5%)                       | 6(12%)                   | 0.008                    |
| Valve Failure             | 0(0%)                         | 0(0%)                  | 0(0%)                            | 0(0%)                     | 5(3%)                       | 3(6%)                    | 0.2596                   |
| Ongoing myocardial ischemia| 1(1%)                         | 0(0%)                  | 0(0%)                            | 0(0%)                     | 3(2%)                       | 1(2%)                    | 0.7951                   |
| Arrhythmia                | 68(61%)                       | 4(80%)                 | 55(46%)                          | 4(100%)                   | 41(25%)                     | 14(29%)                  | 0.5782                   |
| Hyponatremia              | 41(37%)                       | 4(80%)                 | 38(32%)                          | 1(25%)                    | 31(19%)                     | 13(27%)                  | 0.2412                   |
| Hypoalbuminemia           | 6(5%)                         | 0(0%)                  | 7(6%)                            | 0(0%)                     | 25(15%)                     | 11(22%)                  | 0.5089                   |
| Coagulopathy              | 92(82%)                       | 4(80%)                 | 78(65%)                          | 4(100%)                   | 78(47%)                     | 23(47%)                  | 0.8186                   |
| Death                     | 6(5%)                         | 1(20%)                 | 8(7%)                            | 0(0%)                     | 15(9%)                      | 6(12%)                   | 0.4411                   |

*P values are given only for the comparison between TAVR non-cirrhotic and TAVR cirrhotic patients.

min-SVR surgeries. Thus a detail statistical comparison with the cirrhotic TAVR patients could not be carried out. Further studies are needed to compare TAVR with SAVR and mini-SVR in cirrhotic patients.

There is a difference of opinion about the risk of mortality of TAVR in more advanced cirrhosis. Some studies suggested that for patients with more advanced cirrhosis, the risk of mortality is very high [17,18], while another study showed that advanced cirrhosis should not exclude patients from undergoing TAVR surgery [19].

Although procedural costs are higher with TAVR than SAVR, it is argued that total cost differences for the index hospitalization are marginally higher owing to reductions in length of stay with TAVR. Follow-up costs are also significantly lower with TAVR than with SAVR. Over a lifetime timeframe, TAVR was thus projected to lower total costs by $8000 to $10,000 [20]. However, there is no uniform consensus on this point as the future of TAVR prostheses remains unknown beyond the short term [15]. One of the limitations of our study is that we did not carry out case-based cost calculations to determine cost-effectiveness of TAVR in our patient population.

5. Conclusion

Our data shows that TAVR offers comparable if not superior post-surgical outcomes when compared to current treatment options for aortic valve pathology. It also supports the notion that liver cirrhosis should not preclude patients from cardiac surgery. Although we have not carried out case-based cost studies, considerations of procedural and follow-up costs suggest that TAVR may be a cost-effective option for patients, especially based on the average age and pre-existing comorbidities of patients who underwent this procedure. Our study provides a step toward enabling a patient-centered decision-making process in our medically underserved and low-income patient population.

Provenance and peer review

Not commissioned, externally peer reviewed.

Ethical approval

This retrospective study was reviewed and approved by the Institutional Review Board of Cooper Health System on 09/18/2017 (Reference number 17-132EX). This study has a waiver of consent and HIPAA authorization.

Sources of funding

None.

Author contribution

Maria Winte: data collection, data processing, reviewing. Krysta Contino: data collection, writing, reviewing. Aditi Trivedi: data collection. Nikhita Dharbhamulla: data collection. John Gaughan: statistical analysis. Christopher Deitch: study concept, study design, reviewing. Sangita Phadtare: literature review, study concept, study design, writing, reviewing.

Research registration number

Name of the registry: RegistryReg
Unique Identifying number or registration ID: researchregistry5766
Hyperlink to your specific registration (must be publicly accessible and will be checked): https://www.researchregistry.com/browse-the-registry#home/registrationdetails/5efa0dd97103e90016268c5f/

Guarantor

Sangita Phadtare and Krysta Contino.

Consent

This is a retrospective cohort study based on electronic medical charts review. This study has a waiver of consent and HIPAA authorization. This retrospective study was reviewed and approved by the Institutional Review Board of Cooper Health System on 09/18/2017 (Reference number 17-132EX).

Declaration of competing interest

No conflicts of interest to declare.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2020.07.056.

References

[1] D.H. Adams, J.J. Popma, M.J. Reardon, Transcatheter aortic-valve replacement with a self-expanding prosthesis, N. Engl. J. Med. 371 (10) (2014) 967–968.
[2] S.K. Kodali, M.R. Williams, C.R. Smith, L.G. Svensson, J.G. Webb, R.R. Makkar, G. P. Fontana, T.M. Dewey, V.H. Thourani, A.D. Pichard, et al., Two-year outcomes after transcatheter or surgical aortic-valve replacement, N. Engl. J. Med. 366 (18) (2012) 1686–1695.
[3] M.J. Reardon, D.H. Adams, N.S. Kleiman, S.J. Yakubov, J.S. Coselli, G.M. Deeb, T. G. Gleason, J.S. Lee, J.B. Hermiller Jr., S. Chetcuti, et al., 2-Year outcomes in
patients undergoing surgical or self-expanding transcatheter aortic valve replacement, J. Am. Coll. Cardiol. 66 (2) (2015) 113–121.

[4] D.J. Kumbhani, S. Banerjee, 3-Year results of a TAVR trial in high surgical risk patients, J. Am. Coll. Cardiol. 67 (22) (2016) 2565–2574.

[5] G.M. Deeb, M.J. Reardon, S. Chetcuti, H.J. Patel, P.M. Grossman, S.J. Yakubov, N.S. Kleinman, J.S. Coselli, T.G. Gleason, J.S. Lee, et al., 3-Year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement, J. Am. Coll. Cardiol. 67 (22) (2016) 2565–2574.

[6] M.J. Mack, M.B. Leon, C.R. Smith, D.C. Miller, J.W. Moses, E.M. Tuzcu, J.G. Webb, P.S. Douglas, W.N. Anderson, E.H. Blackstone, et al., 3-Year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement, J. Am. Coll. Cardiol. 67 (22) (2016) 2565–2574.

[7] M.J. Mack, M.B. Leon, C.R. Smith, D.C. Miller, J.W. Moses, E.M. Tuzcu, J.G. Webb, P.S. Douglas, W.N. Anderson, E.H. Blackstone, et al., 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial, Lancet 385 (2015) 2477–2484.

[8] N.E. Moat, P. Ludman, M.A. de Belder, B. Bridgewater, A.D. Cunningham, C.P. Young, M. Thomas, J. Kovac, T. Spyt, P.A. McCarthy, et al., Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry, J. Am. Coll. Cardiol. 58 (20) (2011) 2130–2138.

[9] D. Paparelli, G. Santarpino, P.G. Malvindi, M. Moscarelli, A. Marchese, P. Guida, C. Carbone, R. Gregorini, L. Martinelli, C. Comoglio, et al., Minimally invasive versus transcatheter aortic valve replacement: a multicenter study, J. Heart & Vascular. 23 (2019) 100362.

[10] P. Genereux, D.J. Cohen, M. Mack, M.J. Rodes-Cabau, M. Yadav, K. Xu, R. Parvataneni, R. Hahn, S.K. Kodali, J.G. Webb, et al., Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement, J. Am. Coll. Cardiol. 64 (24) (2014) 2605–2615.

[11] D. Siqueira, A. Abizaid, J.E. Bavaria, N.D. Desai, D. Jagasia, W.Y. Szeto, et al., Outcomes of transcatheter aortic valve replacement in patients with chronic liver disease, Cathet. Cardiov. Interv. 86 (2015) 888–894.

[12] A. Modi, H.A. Vohra, C.W. Barlow, Do patients with liver cirrhosis undergoing cardiac surgery have acceptable outcomes? J. Heart & Vascular. 23 (2019) 100362.

[13] C.H. Lin, R.B. Hsu, Cardiac surgery in patients with liver cirrhosis: risk factors for predicting mortality, J. Gastroenterol. 20 (35) (2014) 12608–12614.

[14] S.J. Baron, K. Wang, A.E. Magnuson, B. Whisenant, A. Brieke, M. Rinaldi, W.T. Abraham, et al., Cost-effectiveness of transcatheter mitral valve repair versus medical therapy in patients with heart failure and secondary mitral regurgitation: results from the COAPT trial, Circulation 140 (2019) 1881–1891.